{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:55:46Z","timestamp":1784166946194,"version":"3.55.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Some patients with chronic coronary syndromes undergo invasive procedures but the efficacy of such interventions remains to be robustly established by randomised sham-controlled trials (RCTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To determine the sham effect in patients with chronic coronary syndromes enrolled in RCTs by performing a systematic review and meta-analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In April 2022, we performed a literature search for published patient-blind RCTs (CENTRAL, MEDLINE\u00ae, PsycINFO, and reference lists) with sham procedures, reporting the pre-post effects in the invasive sham arm among patients with Canadian cardiovascular society (CCS) angina or angina equivalents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>16 RCTs were included with 546 patients in the sham arm. Pooled results showed that sham interventions were associated with: improvement of 7% (95% CI 2\u201311%; I<jats:sup>2<\/jats:sup>\u2009=\u20090%) in exercise time; decrease of 0.78 (95% CI \u2212\u20091.10 to \u2212\u20090.47; I<jats:sup>2<\/jats:sup>\u2009=\u200975%) in CCS angina class; decrease of 53% (95% CI 24\u201371%; I<jats:sup>2<\/jats:sup>\u2009=\u200996%) and 25% (95% CI 20\u201329%; I<jats:sup>2<\/jats:sup>\u2009=\u20090%) in anginal episodes and nitroglycerine (NTG) use, respectively. Pooled results also showed an improvement in the physical functioning, angina frequency, treatment satisfaction, and disease perception domains of the Seattle Angina Questionnaire (SAQ).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Sham interventions in patients with chronic coronary syndromes were associated with a significant decrease in anginal episodes, NTG use, and CCS angina class and increased SAQ quality of life and exercise time. These results highlight the need for previous non sham-controlled trials to be interpreted with caution, and the importance of new invasive interventions to be evaluated versus a sham procedure.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02658-x","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T12:10:24Z","timestamp":1652530224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Catarina","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udio","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo M.","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim J.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Caldeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"issue":"3","key":"2658_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Achenbach S, Agewall S, Barbato E, Bax JJ, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J"},{"key":"2658_CR2","doi-asserted-by":"crossref","unstructured":"Bauersachs R, Zeymer U, Bri\u00e8re JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019.","DOI":"10.1155\/2019\/8295054"},{"issue":"15","key":"2658_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1056\/NEJMoa070829","volume":"356","author":"W Boden","year":"2007","unstructured":"Boden W, O\u2019Rourke R, Teo K, Hartigan P, Maron D, Kostuk W, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503\u201316.","journal-title":"N Engl J Med"},{"issue":"11","key":"2658_CR4","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa1205361","volume":"367","author":"B De Bruyne","year":"2012","unstructured":"De Bruyne B, Pijls NHJ, Kalesan B, Barbato E, Tonino PAL, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991\u20131001.","journal-title":"N Engl J Med"},{"issue":"10115","key":"2658_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","volume":"391","author":"R Al-Lamee","year":"2017","unstructured":"Al-Lamee R, Thompson D, Dehbi HM, Sen S, Tang K, Davies J, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. The Lancet. 2017;391(10115):31\u201340.","journal-title":"The Lancet"},{"issue":"25","key":"2658_CR6","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1056\/NEJM197906213002508","volume":"300","author":"H Bleich","year":"1979","unstructured":"Bleich H, Moore M, Benson H, McCallie D. Angina pectoris and the placebo effect. N Engl J Med. 1979;300(25):1424\u20139.","journal-title":"N Engl J Med"},{"key":"2658_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1176\/appi.psychotherapy.1964.18.s1.73","volume":"18","author":"AK Shapiro","year":"1961","unstructured":"Shapiro AK. Factors contributing to the placebo effect, their implications for psychotherapy. Am J Psychother. 1961;18:73\u201388.","journal-title":"Am J Psychother"},{"key":"2658_CR8","first-page":"372","volume":"2021","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. The BMJ. 2020;2021:372.","journal-title":"The BMJ"},{"issue":"5","key":"2658_CR9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1161\/CIRCOUTCOMES.114.000967","volume":"7","author":"PS Chan","year":"2014","unstructured":"Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the seattle angina questionnaire. Circ Cardiovasc Quality Outcomes. 2014;7(5):640\u20137.","journal-title":"Circ Cardiovasc Quality Outcomes"},{"issue":"1","key":"2658_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14(1):1\u201313.","journal-title":"BMC Med Res Methodol"},{"issue":"14898","key":"2658_CR11","first-page":"526","volume":"366","author":"J Sterne","year":"2019","unstructured":"Sterne J, Savovi\u0107 J, Page M, Elbers R, Blencowe N, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366(14898):526.","journal-title":"BMJ"},{"issue":"11","key":"2658_CR12","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"key":"2658_CR13","doi-asserted-by":"publisher","DOI":"10.4135\/9781412961288","volume-title":"Encyclopedia of research design","author":"N Salkind","year":"2010","unstructured":"Salkind N. Encyclopedia of research design. California: Thousand Oaks; 2010."},{"issue":"7109","key":"2658_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"June","key":"2658_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method. Biometrics. 2000;56(June):455\u201363.","journal-title":"Biometrics"},{"issue":"1","key":"2658_CR16","first-page":"8","volume":"9","author":"GH Guyatt","year":"2009","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Chin J Evid Based Med. 2009;9(1):8\u201311.","journal-title":"Chin J Evid Based Med"},{"issue":"22","key":"2658_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1056\/NEJM195905282602204","volume":"260","author":"LA Cobb","year":"1959","unstructured":"Cobb LA, Thomas GI, Dillard DH, Meredino A, Bruce RA. An evaluation of internal-mammary-artery ligation by a double-blind technic. N Engl J Med. 1959;260(22):1115\u20138.","journal-title":"N Engl J Med"},{"issue":"17","key":"2658_CR18","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/01.CIR.0000015982.70785.B7","volume":"105","author":"DW Losordo","year":"2002","unstructured":"Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, et al. Phase 1\/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002;105(17):2012\u20138.","journal-title":"Circulation"},{"issue":"9","key":"2658_CR19","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.amjcard.2004.01.032","volume":"93","author":"M Salem","year":"2004","unstructured":"Salem M, Rotevatn S, Stavnes S, Brekke M, Vollset SE, Nordrehaug JE. Usefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. Am J Cardiol. 2004;93(9):1086\u201391.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2658_CR20","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1016\/j.jacc.2005.06.079","volume":"46","author":"MB Leon","year":"2005","unstructured":"Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, et al. A blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. J Am Coll Cardiol. 2005;46(10):1812\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"2658_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","volume":"45","author":"J Kastrup","year":"2005","unstructured":"Kastrup J, J\u00f8rgensen E, R\u00fcck A, T\u00e4gil K, Glogar D, Ruzyllo W, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A 165 gene therapy in patients with stable severe angina pectoris: A randomized double-blind placebo-controlled study: The Euroinject One trial. J Am Coll Cardiol. 2005;45(7):982\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2658_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/ccd.20859","volume":"68","author":"S Fuchs","year":"2006","unstructured":"Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A, et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv. 2006;68(3):372\u20138.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"25","key":"2658_CR23","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1161\/CIRCULATIONAHA.106.687376","volume":"115","author":"DW Losordo","year":"2007","unstructured":"Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: A phase I\/IIa double-blind, randomized controlled trial. Circulation. 2007;115(25):3165\u201372.","journal-title":"Circulation"},{"issue":"24","key":"2658_CR24","doi-asserted-by":"publisher","first-page":"2998","DOI":"10.1093\/eurheartj\/ehm485","volume":"28","author":"HF Tse","year":"2007","unstructured":"Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, et al. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J. 2007;28(24):2998\u20133005.","journal-title":"Eur Heart J"},{"issue":"19","key":"2658_CR25","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1001\/jama.2009.685","volume":"301","author":"J van Ramshorst","year":"2009","unstructured":"van Ramshorst J, Bax JJ, Beeres SLMA, Dibbets-Schneider P, Roes SD, Stokkel MPM, et al. Intramyocardial Bone Marrow Cell Injection for Chronic Myocardial Ischemia. JAMA. 2009;301(19):1997.","journal-title":"JAMA"},{"issue":"2","key":"2658_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000320217","volume":"117","author":"S Wang","year":"2010","unstructured":"Wang S, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology. 2010;117(2):140\u20137.","journal-title":"Cardiology"},{"issue":"4","key":"2658_CR27","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","volume":"109","author":"DW Losordo","year":"2011","unstructured":"Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428\u201336.","journal-title":"Circ Res"},{"issue":"7","key":"2658_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.4244\/EIJV6I7A140","volume":"6","author":"J Kastrup","year":"2011","unstructured":"Kastrup J, Jorgensen E, Fuchs S, Nikol S, Botker HE, Gyongyosi M, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention. 2011;6(7):813\u20138.","journal-title":"EuroIntervention"},{"issue":"3","key":"2658_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ahj.2011.11.020","volume":"163","author":"EC Perin","year":"2012","unstructured":"Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel D, et al. Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J. 2012;163(3):415-421.e1.","journal-title":"Am Heart J"},{"issue":"6","key":"2658_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1056\/NEJMoa1402556","volume":"372","author":"S Verheye","year":"2015","unstructured":"Verheye S, Jolic\u0153ur EM, Behan MW, Pettersson T, Sainsbury P, Hill J, et al. Efficacy of a device to narrow the coronary sinus in refractory Angina. N Engl J Med. 2015;372(6):519\u201327.","journal-title":"N Engl J Med"},{"issue":"15","key":"2658_CR31","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","volume":"9","author":"TJ Povsic","year":"2016","unstructured":"Povsic TJ, Henry TD, Traverse JH, Fortuin FD, Schaer GL, Kereiakes DJ, et al. The RENEW trial: efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina. JACC Cardiovasc Interv. 2016;9(15):1576\u201385.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"2658_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.7326\/0003-4819-106-6-793","volume":"106","author":"BD Mark","year":"1987","unstructured":"Mark BD, Hlatky MA, Harrell FEJ, Lee KL, Califf RM, Pryor DB. Exercise treadmill score for predicting prognosis in coronary artery disease. Ann Intern Med. 1987;106(6):793\u2013800.","journal-title":"Ann Intern Med"},{"issue":"9756","key":"2658_CR33","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. The Lancet. 2010;376(9756):1903\u20139.","journal-title":"The Lancet"},{"issue":"15","key":"2658_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393\u2013401.","journal-title":"N Engl J Med"},{"issue":"8","key":"2658_CR35","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375\u201382.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2658_CR36","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"JC Tardif","year":"2009","unstructured":"Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: A 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540\u20138.","journal-title":"Eur Heart J"},{"issue":"26","key":"2658_CR37","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/eurheartj\/ehy220","volume":"39","author":"GS Werner","year":"2018","unstructured":"Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J. 2018;39(26):2484\u201393.","journal-title":"Eur Heart J"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02658-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T12:14:40Z","timestamp":1652530480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2658"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02658-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"3 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participants"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DC has participated in educational meetings and\/or attended conferences or symposia (including travel, accommodation, and\/or hospitality) with Bristol-Myers Squibb, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Merck Serono, Ferrer, Pfizer, Novartis, and Roche\u2009>\u20093\u00a0years; no conflicts of interest\u2009<\u20093\u00a0years. JJF had speaker and consultant fees with Gr\u00fcnenthal, Funda\u00e7\u00e3o MSD (Portugal), TEVA, MSD, Allergan, Medtronic, GlaxoSmithKline, Novartis, Lundbeck, Solvay, BIAL, Merck Serono, Merz, Ipsen, Biogen, Acadia, Allergan, Abbvie, Sunovion-Pharmaceuticals. FJP had consultant and speaker fees with Astra Zeneca, Bayer, BMS, Boehringer Ingelheim and Daiichi Sankyo. There is no any other conflict of interest by the rest of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"223"}}